Posted by Michael Wonder on 28 Sep 2021
FDA grants priority review to ViiV Healthcare’s new drug application for cabotegravir long-acting for prevention of HIV
28 September 2021 - Final FDA decision anticipated by 24 January 2022; if approved, cabotegravir would be the first long-acting therapy for HIV PrEP.
ViiV Healthcare today announced that the U.S. FDA has accepted and granted priority review for a new drug application for investigational, injectable cabotegravir long-acting for pre-exposure prophylaxis, or PrEP.
